比利时儿童ALL/NHL中PEG-ASNase与Erwinia ASNase治疗的前瞻性实时监测
该前瞻性多中心研究在比利时儿童ALL和NHL患者中实时监测PEG-ASNase及Erwinia ASNase活性。无超敏反应者PEG-ASNase谷浓度中位数高;Erwinia给药后第3天活性<100 IU/l的比例显著高于第2天,肌注第2天活性中位数显著高于静注。
要点
- 儿童ALL/NHL治疗中实时监测ASNase活性可行且信息量大
- Erwinia ASNase需密切监测,优选肌注并坚持2天间隔
核心结论
- 儿童ALL和NHL治疗期间监测ASNase活性可行且具有临床信息价值。
- Erwinia ASNase治疗需要密切监测,并最佳地遵循肌注2天间隔给药。
研究设计与样本
- 前瞻性、多中心、实时治疗药物监测研究,在比利时开展。
- PEG-ASNase队列共纳入286例儿童;Erwinia ASNase作为PEG-ASNase超敏反应后的二线治疗,共42例。
主要发现
- 所有无超敏反应患者的PEG-ASNase谷活性中位数均较高。
- Erwinia肌注第2天活性中位数显著高于静注(347 IU/l vs 159 IU/l)。
关键数值与推荐
- Erwinia第2天活性中位数:肌注347 IU/l,静注159 IU/l。
临床怎么用
- 对接受PEG-ASNase或Erwinia ASNase治疗的儿童ALL/NHL患者应开展实时ASNase活性监测。
- Erwinia ASNase治疗时应密切监测活性,并优先采用肌注、遵循2天间隔给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asparaginase (ASNase) is an important anti-leukaemic drug in the treatment of childhood acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL). A substantial proportion of patients develop hypersensitivity reactions with anti-ASNase neutralising antibodies, resulting in allergic reactions or silent inactivation (SI), and characterised by inactivation and rapid clearance of ASNase. We report results of a prospective, real-time therapeutic drug monitoring of pegylated Escherichia coli (PEG-)ASNase and Erwinia ASNase in children treated for ALL and NHL in Belgium. Erwinia ASNase was given as second-line after hypersensitivity to PEG-ASNase. In total, 286 children were enrolled in the PEG-ASNase cohort. Allergy was seen in 11·2% and SI in 5·2% of patients. Of the 42 patients treated with Erwinia ASNase, 7·1% experienced allergy and 2·4% SI. The median trough PEG-ASNase activity was high in all patients without hypersensitivity. After Erwinia administration significantly more day 3 samples had activities <100 IU/l (62·5% vs. 10% at day 2 (D2)). The median D2 activity was significantly higher for intramuscular (IM; 347 IU/l) than for intravenous Erwinia administrations (159 IU/l). This prospective, multicentre study shows that monitoring of ASNase activity during treatment of children with ALL and NHL is feasible and informative. Treatment with Erwinia ASNase warrants close monitoring and optimally adherence to a 2-day interval of IM administrations.
引用
- Mondelaers V, Ferster A, Uyttebroeck A, et al. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. Br J Haematol. 2020. PMID: 32057100. doi:10.1111/bjh.16495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。